183 related articles for article (PubMed ID: 27373496)
41. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
42. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
44. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.
Russell K; Healy B; Pantarotto J; Laurie SA; MacRae R; Sabri E; Wheatley-Price P
Clin Lung Cancer; 2014 May; 15(3):237-43. PubMed ID: 24461300
[TBL] [Abstract][Full Text] [Related]
47. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
48. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
49. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
50. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
51. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
52. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
53. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
54. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D; Tural D; Koca T; Tastekin D; Kaymak Cerkesli A; Basaran H; Gunduz S; Murat Tatli A; Sezgin Goksu S; Uysal M; Kargi A; Kargi B; Koral L; Ibrahim Bassorgun C; Unal D; Mutlu H; Senol Coskun H; Ozdogan M; Bozcuk H
J BUON; 2015; 20(2):573-9. PubMed ID: 26011352
[TBL] [Abstract][Full Text] [Related]
56. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
57. The role of glutamine supplementation in thoracic and upper aerodigestive malignancies.
Papanikolopoulou A; Syrigos KN; Drakoulis N
Nutr Cancer; 2015; 67(2):231-7. PubMed ID: 25629996
[TBL] [Abstract][Full Text] [Related]
58. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
60. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.
Ziel E; Hermann G; Sen N; Bonomi P; Liptay MJ; Fidler MJ; Batus M; Warren WH; Chmielewski G; Sher DJ
J Thorac Oncol; 2015 Oct; 10(10):1475-80. PubMed ID: 26398822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
